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Abstract
Pregnancy is characterized by physiological adjustments in the maternal compartment. In this 
investigation, the influence of pregnancy on maternal liver was examined in CD-1 mice. Dramatic 
changes were observed in the size of the maternal liver during pregnancy. Livers doubled in 
weight from the nonpregnant state to day 18 of pregnancy. The pregnancy-induced hepatomegaly 
was a physiological event of liver growth confirmed by DNA content increase and detection of 
hepatocyte hyperplasia and hypertrophy. Growth of the liver was initiated following implantation 
and peaked at parturition. The expression and/or activities of key genes known to regulate liver 
regeneration, a phenomenon of liver growth compensatory to liver mass loss, were investigated. 
The results showed that pregnancy-dependent liver growth was associated with IL-6, TNF1α, 
NFkB, c-Jun, and IL-1β, but independent of HGF, FGF1, TNFR1, CAR, and PXR. Furthermore, 
maternal liver growth was associated with the activation of hepatic STAT3, β-catenin, and EGFR, 
but pregnancy did not activate hepatic c-Met. The findings suggest that the molecular mechanisms 
regulating pregnancy-induced liver growth and injury-induced liver regeneration exhibit 
overlapping features but are not identical. In summary, the liver of the mouse adapts to the 
demands of pregnancy via a dramatic growth response driven by hepatocyte proliferation and size 
increase. Remarkably, our findings provide a novel mouse model to investigate the regulation of 
hepatocyte proliferation, cell size increase, and liver growth.
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Introduction
Pregnancy induces widespread maternal changes in the structures and functions of virtually 
every organ system, including the brain (1), pancreas (2–4), immune system (5), and 
cardiovascular system (6). These physiological changes represent essential maternal 
adaptations to meet the needs of the development and growth of the placenta and fetus. 
Understanding the physiology of maternal adaptive responses to pregnancy is of particular 
importance to gain insights into pregnancy-associated diseases (7).
Maternal liver exhibits profound changes during pregnancy. Maternal hepatic functional 
adjustments include alterations in drug, lipid, cholesterol, bile acid, and glucose metabolism 
(8–24). Pregnancy-induced changes in liver function tests have been reported in humans, 
including alterations of serum albumin and bilirubin levels, aspartate transaminase and 
alanine transaminase activites, and triglyceride and cholesterol concentrations in the blood 
(25–29). Remarkably, the maternal liver responds to pregnancy by significantly increasing 
its size (8, 11, 30–33). Although this phenomenon was first reported over fifty years ago, 
few efforts have attempted to elucidate mechanisms regulating pregnancy-induced liver 
growth. Our group revealed that maternal liver enlargement during pregnancy is a growth 
response induced by hepatocyte proliferation and also identified concomitant changes in 
hepatic gene expression (34). Williamson and coworkers provided insights into potential 
roles of reproductive hormones, bile acids, and the nuclear receptors mediating bile acid 
signaling in the regulation of pregnancy-induced hepatomegaly (35).
In this investigation, we examined maternal adjustments to pregnancy from embryo 
implantation to parturition in the mouse. Maternal hepatic growth responses to pregnancy 
are characterized by both hepatocyte hyperplasia and hypertrophy. Some mechanisms 
controlling maternal liver growth are shared with mechanisms controlling injury-induced 
liver regeneration, while others are distinct.
Materials and methods
Animals and tissue preparations
CD-1 mice were purchased from Charles River Laboratories, Inc. (Wilmington, MA). 
TNFR1-null mice on a C57BL/6 background were provided by Drs. Kathy F. Roby and Paul 
F. Terranova (University of Kansas Medical Center, Kansas City, KS) (36). C57BL/6 mice 
were obtained from Harlan, Inc. (Indianapolis, IN, USA). The animals were housed in an 
environmentally controlled facility, with lights on from 0600–2000 h, and allowed free 
access to food and water. Timed pregnancies were generated and the presence of a 
copulatory plug in the vagina was designated as gestation day 1. Non-pregnant, pregnant, 
and postpartum non-lactating mice were weighed and sacrificed. Livers and kidneys were 
dissected and weighed. Liver tissues were fixed in formalin and then embedded in paraffin 
for histological analysis, or snap-frozen in liquid nitrogen for total RNA isolation and 
biochemical analysis. Litter sizes for pregnancies ranged from 8–14. Protocols for the care 
and use of animals were approved by the University of Kansas Medical Center Animal Care 
and Use Committee.
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Measurements of total hepatic DNA content
Liver tissues were completely digested overnight at 55°C in a buffer containing 100 mM 
NaCI, 50 mM Tris-HCI (pH 8.0), 25 mM EDTA (pH 8.0), 0.5% SDS, and proteinase K (400 
µg/ml). The digested samples were mixed with PicoGreen dsDNA Quantitation Reagent 
(Molecular Probes, Eugene, OR, USA). The mixed samples were excited at 480 nm and the 
fluorescence emission intensity was measured at 520 nm using a spectrofluorometer. DNA 
concentrations were determined with a standard curve of fluorescence emission intensity 
versus DNA concentration.
Ki-67 immunostaining and mitotic figure and hepatocyte counting
Formalin-fixed and paraffin-embedded liver samples were sectioned and subjected to Ki-67 
immunostaining with a primary Ki-67 antibody (NeoMarkers, Fremont, CA, USA) 
according to the manufacturer’s instructions. Ki67-positive hepatocytes and mitotic figures 
were counted in five low magnification microscope fields of 40x and 20x, respectively, for 
each sample. Formalin-fixed and paraffin-embedded liver sections were stained with 
hematoxylin and eosin (H&E). Hepatocytes were counted with Image-Pro Plus software 
(Media Cybernetics, MD, USA) in at least four low-magnification (40x) microscope fields 
for each sample.
Quantitative real-time polymerase chain reaction (qRT-PCR
Total RNA was isolated from frozen liver tissue using the TRIzol reagent according to the 
manufacturer’s protocol (Invitrogen, Carlsbard, CA, USA). The cDNAs were synthesized 
with total RNA (1 µg) from each sample, diluted 10 times with water, and subjected to qRT-
PCR to quantify mRNA levels using TaqMan probe (Applied Biosystems, Foster City, CA, 
USA). Primers and probes were designed using Primer Express 2.0 (Applied Biosystems, 
Foster City, CA, USA). The probe was labeled with a reporter dye FAM (6-
carborxyfluorescein). TaqMan Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA, USA) was used to prepare the PCR incubations. Primers and probes were added at 
a final concentration of 90 and 125 nmol, respectively, in a total volume of 20 µl. The 
amplification reactions were carried out in the ABI Prism 7900 sequence detection system 
(Applied Biosystems, Foster City, CA, USA) with initial hold steps (50°C for 2 min, 
followed by 95°C for 10 min) and 40 cycles of a 2-step PCR (92°C for 15 seconds, 60°C for 
1 min). The primer (Integrated DNA Technologies, Coralvillem, IA) and probe (Sigma, St. 
Louis, MO, USA) sequences used for qRT-PCR are listed in Table 1. The comparative CT 
method was used for relative quantification of the amount of mRNA for each sample 
normalized to β-actin transcript levels.
Northern analysis
Northern analysis was performed as previously described (37). Briefly, total RNA was 
extracted from frozen liver tissues using Trizol reagent (Invitrogen, Carlsbad, CA, USA). 
Total RNA (20 µg) was separated on 1% formaldehyde-agarose gels and transferred to nylon 
membranes. Blots were probed with a [32P]-labeled cDNA for FGF1. A glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) cDNA was used as an internal reference to ensure equal 
loading and RNA integrity.
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Western analysis
Liver homogenates (40 µg) were separated by polyacrylamide gel electrophoresis under 
reducing conditions. Proteins from the gels were electrophoretically transferred to 
nitrocellulose. Antibodies of signal transducer and activator of transcription 3 (STAT3), 
epidermal growth factor receptor (EGFR), p-EGFR, cyclin E, and cyclin A2 from Epitomics 
(Burlingame, CA, USA); p-STAT3 (Tyr 705), β-catenin, cyclin D1, caspase 3, and 
nonphosphorylated β-catenin from Cell Signaling Technology (Danvers, MA, USA); c-Met 
and p-c-Met from Abcam (Cambridge, MA, USA), and β-actin from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA) were used as probes. Immune complexes were 
detected using the enhanced chemiluminescence system (Pierce, Rockford, IL, USA).
Statistical analysis
Data are shown as mean ± standard error of the mean (SEM) or standard deviation (SD). 
Statistical analyses were performed using one-way analysis of variance. Comparisons of 
means were determined by post-hoc analyses. Significant differences were defined when P < 
0.05.
Results
Pregnancy induces maternal liver mass expansion
Gravimetric responses of maternal livers and kidneys were assessed throughout pregnancy 
and during the post-partum (day 10, non-lactating). As expected, pregnancy-dependent 
increases in maternal liver wet weight (hepatomegaly) were observed (Fig. 1A). In 
comparison with pre-pregnancy liver sizes, the maternal liver mass expansion became 
statistically significant at gestation day 13 and was sustained until the end of pregnancy. 
After parturition, the maternal liver regressed to pre-pregnancy sizes. Two waves of 
significant elevation of the liver-to-body weight ratios were seen during the course of 
gestation (Fig. 1B). The first wave occurred during the first half of pregnancy (gestation 
days 8 to 10), whereas the second wave took place during the second half of gestation 
(gestation days 13 to 15). The postpartum liver exhibited a higher liver-to-body weight ratio 
than determined for nonpregnant mice. In contrast to the liver, there were no significant 
maternal kidney weight changes during pregnancy (Fig. 1C). The results demonstrate that 
pregnancy induces maternal hepatomegaly, which is not generalized to other maternal 
organs.
Pregnancy-induced maternal liver mass increase is driven by hepatocyte hyperplasia and 
hypertrophy
To determine whether liver size increase is the result of hyperplasia and/or hypertrophy of 
hepatocytes, we first measured the total DNA content in the livers of nonpregnant, pregnant 
(gestation days 8, 13, and 18), and day 10 postpartum (non-lactating) CD-1 mice. Liver 
DNA content was significantly increased on gestation days 13 and 18 as compared with 
nonpregnant mice (Fig. 2). Postpartum and nonpregnant mouse liver DNA contents did not 
significantly differ. The changes of hepatic total DNA content resembled the gestational 
pattern of liver weight increase (Fig. 1), suggesting that liver cell proliferation may occur 
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during pregnancy. To confirm this, we performed Ki-67 immunostaining using the livers of 
nonpregnant and pregnant mice to visualize cell proliferation. The numbers of Ki67-positive 
hepatocytes were markedly increased on gestation days 8, 10, 13, 15, and 18 in comparison 
with that in nonpregnant mice (Fig. 3A&B). The increases in the numbers of mitotic figures 
of hepatocytes, an indicator of hepatocytes undergoing cell division, resembled the changes 
in the numbers of Ki67-positive hepatocytes during the course of pregnancy (Fig. 3B&C). 
These findings demonstrate that hepatocyte proliferation contributes to maternal liver mass 
expansion. To estimate whether liver cell hypertrophy is also a mechanism underlying 
maternal liver enlargement, hepatocytes were counted per microscope field in livers from 
non-pregnant and pregnant mice. The results showed that the numbers of hepatocytes per 
microscope field significantly decreased especially during the second half of gestation, 
compared with observations from non-pregnant mice (Fig. 4). The numbers of hepatocytes 
per microscope field in postpartum non-lactating mice resembled hepatocyte densities in 
livers from nonpregnant mice (Fig. 4). The data indicate that hepatocyte hypertrophy also 
contributes to maternal liver mass expansion during pregnancy. Taken together, we conclude 
that pregnancy-induced hepatomegaly is a physiological event of liver growth underlying 
which are hepatocyte hyperplasia and hypertrophy.
To further evaluate pregnancy-induced hepatocyte proliferation, hepatic protein expression 
of several cell cycle regulators was measured. Cyclin E expression was upregulated 
throughout the entire course of pregnancy, whereas cyclin A2 and D1 were dynamically 
regulated (Fig. 5). On gestation day 8 when hepatocyte proliferation was most prominent 
(Fig. 3B), all three cell cycle regulators were activated. However, at gestation days 13 and 
18 when the second and third major waves of hepatocyte proliferation occurred (Fig. 3B), 
cyclin E and A2 expression was dramatically elevated, while cyclin D1 was downregulated. 
The results suggest distinct mechanisms regulating hepatocyte proliferation at different 
stages of maternal liver growth.
Pregnancy-induced liver growth is associated with a subset of genes involved in liver 
regeneration
To gain insights into the molecular mechanisms responsible for maternal hepatic growth 
response to pregnancy, the expression of several genes known to be involved in liver 
regeneration was evaluated in nonpregnant and pregnant mice (Fig. 6). Hepatic mRNA 
levels of IL-6 and TNF1α, two proinflammatory factors crucial for regulating the early 
regenerative response of the liver (38–39), were significantly upregulated during the course 
of gestation (Fig. 6A & B). Increases of hepatic expression of NFκB and c-Jun transcripts, 
encoding two transcription factors regulating hepatocyte proliferation in response to liver 
mass loss (40), was evident during the first half of pregnancy (Fig. 6C & D). Hepatic 
expression of IL-1β, a factor that curbs hepatocyte DNA synthesis during liver regrowth 
(41), was elevated during pregnancy and following parturition (Fig. 6E). Collectively, the 
dynamic changes in expression of this subset of genes implicated as regulators of injury-
induced liver regeneration suggest that they may also participate in regulating maternal 
hepatic growth responses to pregnancy.
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Hepatic transcript levels of HGF and FGF1, two potent growth factors stimulating cell 
proliferation during liver regeneration (42–43), were either not significantly affected by 
pregnancy (Fig. 6F) or even decreased with the progression of pregnancy (Fig. 6G). 
Increases of hepatic expression of both HGF and FGF1 genes were seen postpartum (Fig. 
6F&G). These observations indicate that pregnancy-induced maternal hepatic growth is 
probably regulated by factors other than hepatic HGF and FGF1.
Deficiency of TNFR1 has no significant impact on pregnancy-dependent liver growth
TNFR1-null mice display disruptions in liver regeneration (44–46). This prompted us to 
examine whether TNFR1 participates in the regulation of maternal liver growth induced by 
pregnancy. Maternal livers were collected and weighed from nonpregnant and pregnant 
(gestation days 13 and 18) wild-type and TNFR1-null C57BL/6 mice. Both wild-type and 
TNFR1 null mice exhibited pregnancy-dependent increases in liver growth (Fig. 7). The 
results indicate that lack of TNFR1 signaling does not significantly affect pregnancy-
dependent liver growth.
Hepatic PXR and CAR are not activated during pregnancy
PXR and CAR are two primary xenobiotic receptors that regulate the expression of genes 
involved in phase I, phase II, and phase III metabolism of xenobiotics and endobiotics (47–
48). Notably, upon activation, both PXR and CAR induce hepatocyte proliferation, resulting 
in hepatomegaly (49–50). In addition, PXR participates in regulating liver regeneration (51). 
Thus, determination of the expression and functional status of these two nuclear receptors in 
livers from pregnant mice provides insight into their participation in pregnancy-induced 
hepatomegaly. Therefore, transcript levels of PXR, Cyp3a11 (a prototypical PXR target 
gene), CAR, and Cyp2b10 (a prototypical CAR target gene) were measured by qRT-PCR 
during the course of gestation (Fig. 8). Hepatic PXR (Fig. 8A), Cyp3a11 (Fig. 8B), CAR 
(Fig. 8C), and Cyp2b10 (Fig. 8D) mRNAs did not exhibit significant increases during 
pregnancy. In contrast, significant pregnancy-dependent decreases of hepatic Cyp3a11 (Fig. 
8B), CAR (Fig. 8C), and Cyp2b10 (Fig. 8D) transcript levels were observed at midgestation 
(gestation day 10 and/or 11). Thus hepatic PXR and CAR are not activated by pregnancy, 
suggesting that these two nuclear receptors are unlikely to be the mediators of maternal 
hepatic growth response to pregnancy.
A subset of signaling molecules regulating liver regeneration are activated in maternal 
liver during pregnancy
Both pregnancy-induced liver growth and liver regeneration are driven by hepatocyte 
proliferation (current study and (42)). The functional states of several signaling molecules 
known to regulate liver regeneration were investigated in non-pregnant and pregnant mice. 
Hepatic protein levels of phosphorylated STAT3 were markedly increased throughout 
gestation, indicating robust activation of the molecule, while gestation-dependent increases 
in hepatic content of total STAT3 protein were much less striking (Fig. 9). Hepatic non-
phosphorylated β-catenin exhibited an increase especially during the second half of 
pregnancy (Fig. 9), in parallel with the maternal liver growth pattern (Fig. 1), whereas total 
β-catenin did not show marked changes (Fig. 9). The results demonstrate that pregnancy 
activates STAT3 and β-catenin-mediated signaling pathways in the maternal liver. Hepatic 
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phosphorylated EGFR showed increases from gestation day 8 to 15, followed by a decrease 
prior to parturition (gestation day 18), without changes in total EGFR throughout pregnancy 
(Fig. 9). The data indicate that hepatic EGFR signaling is dynamically regulated by 
pregnancy. Surprisingly, both phosphorylated and total c-Met, a receptor mediating potent 
mitogenic effect of HGF during liver regeneration (39, 42), did not exhibit increased hepatic 
expression during pregnancy (Fig. 9). The finding indicates that c-Met may not be a major 
player in mediating maternal hepatic growth response to pregnancy.
Additionally, liver regeneration is accompanied by hepatic apoptosis (39, 42). To determine 
whether this event also occurs during maternal liver growth, hepatic caspase 3 protein was 
examined in non-pregnant and pregnant mice. Unexpectedly, although total caspase 3 
protein level showed an increase during the first half of pregnancy (Fig. 9), cleaved caspase 
3 was not detected at all the time points examined (data not shown). The data suggest that 
apoptosis may not be a major event during pregnancy-induced maternal liver growth.
Discussion
The current study revealed that significant liver growth takes place during pregnancy in the 
mouse. In normal conditions, the liver is a largely quiescent organ despite its large metabolic 
load, maintaining a steady mass, which is controlled by a delicate balance between cell gain 
and cell loss (52). A very small proportion of hepatocytes (< 0.01%), the major structural 
and functional cells in the liver, undergo mitosis at any given time (38, 52). However, a high 
capacity of hepatocyte replication and hepatic regeneration can be elicited with an 
appropriate stimulus. Pathological stimuli, acute or chronic liver injuries induced by various 
insults, including toxins, drug toxicity, viral infection, or surgical resection, can trigger the 
hepatic regenerative response manifested by hepatocyte proliferation to replace the damaged 
tissue (53). This phenomenon of hepatic regeneration is also considered as compensatory 
growth of the liver (39). Chemical stimuli, including certain xenobiotics (e.g. barbiturates 
and pregnenolone 16α-carbonitrile), which are capable of activating specific nuclear 
receptors, such as PXR and CAR, induce hepatocyte proliferation and liver enlargement 
(hepatomegaly), increasing the capacity of the liver for xenobiotic detoxification (54–55). 
This phenomenon represents a hepatic adaptive response to alleviate xenobiotic stress (49). 
In this report, pregnancy was identified as a physiological stimulus capable of stimulating 
maternal liver growth to meet the metabolic needs of the growing placenta and fetus. 
Therefore, pregnancy-induced maternal hepatic growth response provides a novel model to 
investigate hepatocyte proliferation and liver growth regulation.
Our report demonstrates that maternal liver growth during pregnancy is driven by 
hepatocyte hyperplasia and hypertrophy. Several waves of hepatocyte proliferation, 
manifested by increases in the numbers of Ki67-positive hepatocytes and mitotic figures and 
in maternal hepatic DNA content (Fig. 3), were evident as pregnancy progresses. The most 
prominent waves of hepatocyte proliferation took place on gestation days 8, 13, and 15 (Fig. 
3). Hepatocyte hypertrophy was concomitant with maternal liver mass expansion, especially 
during the second half of pregnancy (Fig. 4). It is noteworthy that, by examining non-
pregnant and gestation day 18 livers, Williamson’s group observed gestation-dependent 
increases in the numbers of Ki67-positive heaptocytes and hepatocyte hypertrophy, whereas 
Dai et al. Page 7
Exp Biol Med (Maywood). Author manuscript; available in PMC 2015 March 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
mitotic figures were not seen (35). Thus, it was concluded that pregnancy-induced liver 
growth is mainly a result of hepatocyte hypertrophy caused by the cell cycle arrest before 
mitosis. However, by investigating non-pregnant and gestation days 8, 10, 11, 13, 15, and 18 
livers, we saw gestation-dependent increases in both the numbers of Ki67-positive 
hepatocytes and mitotic figures at several gestation days, in addition to hepatocyte 
hypertrophy (Fig. 3). Here, our conclusion is that hepatocyte proliferation and size increase 
are the driving forces for maternal liver growth during pregnancy.
We noticed that although maternal liver mass was increased during the first half of 
pregnancy, statistical significance between non-pregnant and pregnant livers in liver weight 
was not achieved (Fig. 1). Robust maternal liver mass expansion occurred during the second 
half of pregnancy (Fig. 1). Likewise, in the mouse model of 70% partial hepatectomy, 
hepatocyte proliferation peaks at 36 hours after surgery, whereas significant liver mass 
increases are not observed until several days following the hepatocyte proliferation peak (51, 
56). Thus pregnancy-dependent liver mass expansion is an outcome of a complicated 
biological process associated with an initial increase in cell proliferation and subsequent 
hepatocyte hypertrophy and tissue remodeling.
Our studies have identified three major waves of maternal hepatocyte proliferation during 
the course of gestation, which may be regulated by different mechanisms. On gestation day 
8 when the first wave of maternal hepatocyte proliferation occurred (Fig. 3), cyclins E, A2, 
and D1 were all upregulated (Fig. 5). In contrast, on gestation days 13 and 18 when the 
second and third major waves of hepatocyte proliferation took place (Fig. 3), cyclins E and 
A2 were activated without participation of cyclin D1 in the cell cycle (Fig. 5). It has been 
demonstrated that cyclin D1 is not essential for hepatocyte proliferation induced by 
mitogenic stimuli and the overexpression of cyclin E may compensate for the lack of cyclin 
D1 (57). Therefore, it may not be a surprise in observing a disconnection between maternal 
hepatocyte proliferation and cyclin D1. Notably, on gestation day 11, activation of cyclin E 
and D1 was not accompanied by proliferation of hepatocytes (Fig. 3&5), but instead 
nonparenchymal cells (data not shown). Our findings implicate stage- and cell type-
dependent regulation of the cell cycle by different mitogens or signaling pathways in the 
maternal liver during the course of gestation.
Our studies indicate that pregnancy-induced liver growth and liver regeneration are 
regulated by some molecular mechanisms, which are shared and others, which are unique. 
Liver regeneration is a well-orchestrated process associated with signaling cascades 
involving growth factors, cytokines, and matrix remodeling (42). Several genes known to 
participate in the regulation of liver regeneration, including IL-6, TNF1α, NFkB, c-Jun, and 
IL-1β, were upregulated in a stage-dependent manner during the course of pregnancy (Fig. 
6). The findings suggest that these genes may also be involved in the regulation of maternal 
hepatic growth response to pregnancy. However, unlike liver regeneration, maternal 
hepatocytes undergo several waves of proliferation and concomitantly increase their sizes in 
response to increasing metabolic demands from maternal, placental, and fetal compartments. 
At this juncture, it remains an open question how these genes are integrated into the 
regulatory machinery responsible for maternal liver growth. Remarkably, STAT3, β-catenin, 
and EGFR are activated in maternal liver by pregnancy (Fig. 9). STAT3 is required for 
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hepatocyte DNA synthesis and survival in the acute phase of liver regeneration (58). The 
essential roles of β-catenin, an integral component of the Wnt signaling pathway, in liver 
growth, development, and regeneration have been extensively studied (59). EGFR mediates 
signalings of a number of growth factors, such as EGF, TGFα, and heparin-binding EGF, 
that drive cell cycle progression during liver regeneration (39). In our studies, increases in 
EGFR phosphorylation were seen in maternal livers at most of the time points examined 
(Fig. 9). Thus, STAT3, β-catenin, and EGFR together with other molecules mentioned 
above may represent some mechanisms shared by pregnancy-induced liver growth and liver 
regeneration.
On the other hand, our investigation provides several lines of evidence to support our notion 
that the regulatory mechanisms underlying maternal hepatic growth response to pregnancy 
are distinct from mechanisms controlling liver regeneration. HGF, the most potent direct 
mitogen for hepatocytes identified so far, has been demonstrated as an initiator of liver 
regeneration and signaling by HGF appears as the most irreplaceable contributor to liver 
regeneration (42). Targeted genetic elimination of HGF receptor from the liver leads to a 
compromised regenerative response (60–61). Surprisingly, maternal hepatic HGF mRNA 
expression and the functional status of its receptor c-Met were not significantly affected by 
pregnancy (Fig. 6F &9). As a potent mitogen for hepatocytes, FGF1 is also considered to be 
a modulator of liver regeneration (43). However, hepatic FGF1 expression declines as 
pregnancy advances (Fig. 6G). TNFR1-mediated TNF signaling is critical for the initiation 
of liver regeneration induced by both partial hepatectomy and exposure to toxic chemicals. 
TNFR1 deficiency results in severe suppression of cell proliferation during liver 
regeneration (44–46). In contrast, genetic deletion of TNFR1 did not significantly alter the 
liver growth pattern during pregnancy (Fig. 7). Moreover, PXR and CAR, which participate 
in regulating liver regeneration (51, 62), were not activated by pregnancy (Fig. 8). These 
two nuclear receptors can be activated by naturally occurring steroid hormones, such as 
pregnenolone and progesterone, and other endobiotics, such as bilirubin and bile acids (47, 
55, 63). It is surprising that, in an environment with high concentrations of steroid hormones 
required for maintaining pregnancy, these two nuclear receptors are not activated. We 
conclude that pregnancy-induced maternal liver growth and injury-induced liver 
regeneration exhibit similarities and differences in their regulation.
A recent report demonstrated that the aged maternal liver regenerates via hepatocyte 
hypertrophy after partial hepatectomy during pregnancy (64). The finding indicates potent 
effects of pregnancy on maternal liver regrowth after massive mass loss. Notably, other 
recent reports highlighted the role of placental hormones, such as prolactin and placental 
lactogens, in mediating maternal pancreatic growth response to pregnancy (3–4). Whether 
these hormones take part in regulating maternal liver growth during pregnancy is under 
investigation.
In summary, the current study revealed that the liver of the mouse adapts to the demands of 
pregnancy via a significant growth response induced by hepatocyte hyperplasia and 
hypertrophy. Gestational-dependent maternal hepatic growth occurs post-implantation and 
coincides with the growth and development of the placenta and fetus. The regulatory 
machineries controlling pregnancy (physiological)-induced liver growth and injury 
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(pathological)-induced liver regrowth possess commonalities and differences. Our study 
provides insight into a novel mouse model for investigating the regulation of hepatocyte 
proliferation and liver growth. Further investigation needs to be performed to evaluate the 
maternal hepatic functional changes induced by pregnancy and the molecular and cellular 
mechanisms governing the hepatic adaptive response to pregnancy. This will not only 
further our understanding of liver physiology during pregnancy, but also provide insights 
into mechanisms underlying pregnancy-associated liver diseases, as well as predict the 
influence of pregnancy on drug metabolism.
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Fig. 1. Maternal liver and kidney weight responses to pregnancy
Livers and kidneys were collected and weighed from non-pregnant (NP), pregnant (gestation 
days 4, 8, 10, 11, 13, 15, and 18), and day 10 postpartum (non-lactating; PP) CD-1 mice. 
Liver weights (A), liver-to-body weight ratios (B), and kidney weights (C) are presented. 
Data are expressed as mean ± SEM (n = 5). Asterisks indicate P < 0.05. Note that the liver, 
but not kidney, responds to pregnancy by net weight gain and increase of liver-to-body 
weight ratio.
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Fig. 2. Measurement of total liver DNA content
Liver tissues collected from non-pregnant (NP), pregnant (gestation days 11, 18, and 21), 
postpartum day 10 (non-lactating; PP) CD-1 mice were completely digested overnight. Total 
hepatic DNA content was measured using PicoGreen dsDNA Quantitation Reagent 
(Molecular Probes) according to the manufacturer’s instructions. DNA concentrations were 
determined with a standard curve of fluorescence emission intensity versus DNA 
concentration. Data are expressed as mean ± SEM (n = 5). Asterisks indicate P < 0.05. Note 
that the change of total hepatic DNA content resembled the gestational pattern of liver 
weight change.
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Fig. 3. Ki-67 immunostaining in liver tissue
Liver tissues were collected from nonpregnant (NP), pregnant (gestation days 4, 8, 10, 11, 
13, 15, and 18), and day 10 postpartum (non-lactating; PP) CD-1 mice, fixed in formalin, 
and embedded in paraffin. Liver tissue sections were prepared and Ki-67 immunostaining 
was performed. The nuclei of Ki67-positive cells were stained dark brown. (A) 
Representative liver sections immunohistochemically stained for Ki-67 are shown for 
nonpregnant and pregnant (gestation days 8, 13, and 18) mice. (B) Ki67-positive 
hepatocytes and (C) hepatocyte mitotic figures were counted (40×optical field) and the 
results are shown as mean per field ± SD (n = 3 to 5). Asterisks indicate the level of 
significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Note that hepatocyte proliferation 
was detected in the livers of pregnant, but not nonpregnant, mice and was most prominent 
on gestation days 8, 13, and 18.
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Fig. 4. Determination of the number of hepatocytes per microscopic field
Liver tissues were collected from nonpregnant (NP), pregnant (gestation days 8, 10, 11, 13, 
15, and 18), and day 10 postpartum (non-lactating; PP) CD-1 mice, fixed in formalin, and 
embedded in paraffin. Liver tissue sections were subjected to hematoxylin and eosin 
staining. Hepatocytes were counted (40 × optical field) with Image-Pro Plus software 
(Media Cybernetics, MD) and the results are shown as mean per field ± SD (n = 3 to 5). 
Asterisks indicate the level of significance (***, P < 0.001). Note the gestation-dependent 
reduction in the number of hepatocytes per field.
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Fig. 5. Protein expression of cell cycle regulators in the liver
Liver tissues from nonpregnant (NP) and gestation days 8, 11, 13, 15, and 18 CD-1 mice 
were homogenized. Western blotting was performed on tissue homogenates using cyclin E, 
A2, and D1 antibodies. β-actin protein levels were used as loading controls. Note activation 
of cell cycle regulators by pregnancy.
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Fig. 6. Hepatic expression of genes involved in liver regeneration during pregnancy
Total RNA was prepared from liver tissues of nonpregnant (NP), pregnant (gestation days 4, 
8, 10, 11, 13, 15, and 18), and day 10 postpartum (non-lactating; PP) CD-1 mice, 
respectively. Hepatic mRNA levels of IL-6 (A), TNF1α (B), NFκB (C), c-Jun (D), IL-1β 
(E), and HGF (D) were quantified by real-time PCR and are expressed as mean of fold 
changes compared to nonpregnant controls ± SD (n = 3 for each group). Asterisks indicate 
the level of significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Hepatic gene expression 
of FGF1 (G) was analyzed by northern blot. Twenty μg of total RNA was loaded on 1% 
agarose gels. cDNA probe for FGF1 was labeled with alpha-[32P] dCTP. G3PDH served as 
an internal control demonstrating equal loading and RNA integrity. Note that the genes 
indicated exhibited differential expression patterns during pregnancy.
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Fig. 7. Maternal liver weight responses to pregnancy in wild-type (WT) and TNFR1-null (KO) 
mice
Livers were isolated and weighed from non-pregnant (NP) and gestation days 13 and 18 
pregnant WT and KO mice. Data are expressed as mean of weight (g) ± SEM. Asterisks 
indicate P < 0.05 (n = 5). Note the lack of a significant impact of TNFR1 signaling on 
pregnancy-induced liver growth.
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Fig. 8. Hepatic gene expression of PXR, Cyp3a11, CAR, and Cyp2b10 during pregnancy
Total RNA was prepared from liver tissues of nonpregnant (NP), pregnant (gestation days 4, 
8, 11, 13, 15, and 18), and day 10 postpartum (non-lactating; PP) mice, respectively. Hepatic 
mRNA levels for PXR (A), Cyp3a11 (B), CAR (C), and Cyp2b10 (D) were measured by 
qRT-PCR and are expressed as means of fold changes compared to nonpregnant controls ± 
SD (n = 3 for each group). Asterisks indicate P < 0.05. Note the absence of a pregnancy-
dependent increase in hepatic mRNA levels for each of these genes.
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Fig. 9. Protein expression and functional states of a subset of signaling molecules regulating liver 
regeneration during pregnancy
Liver tissues from nonpregnant (NP) and gestation days 8, 11, 13, 15, and 18 CD-1 mice 
were homogenized. Western blotting was performed on tissue homogenates using antibodies 
against the proteins indicated. β-actin protein levels were used as loading controls. Note the 
activation of STAT3 and β-catenin by pregnancy.
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Table 1
Sequences of Primers and Probes for Quantitative Real Time PCR
Genes Primers (5’-3’) Probes (5’-3’)
IL-6 Forward: GTTGCCTTCTTGGGACTGATG
Reverse: GGGAGTGGTATCCTCTGTGAAGTCT
TGGTGACAACCACGGCCTTCCC
TNF1α Forward: ACAAGGCTGCCCCGACTAC
Reverse: TTTCTCCTGGTATGAGATAGCAAATC
TGCTCCTCACCCACACCGTCAGC
NFkB Forward: TGGCAGCTCTTCTCAAAGCA
Reverse: CCAAGAGTCGTCCAGGTCATAGA
ACCCCCTGGTGGAGAACTTTGAGCC
c-Jun Forward: TCTTCATTTTCTCACCAACTGCTT
Reverse: CTCTCCAAATGCTCCCCAAA
CGCGGCTCCTGCACCGGT
IL-1β Forward: AAGATGAAGGGCTGCTTCCA
Reverse: GTGCTGCTGCGAGATTTGAA
CCTTTGACCTGGGCTGTCCTGATGA
HGF Forward: AAGGGACGGTATCCATCACTAAGA
Reverse: GGGTTGAAGGCACGACACAT
TGGCATCAAATGCCAGCCTTGGAA
PXR Forward: CAGTTGCTGCGCATCCAA
Reverse: TGCTGCTAAATAACTCTTGCATGAG
TCGCACCCCTTTGCCACCCC
Cyp3a11 Forward: TCACAGACCCAGAGACGATTAAGA
Reverse: CCCGCCGGTTTGTGAAG
CCCGCCGGTTTGTGAAG
CAR Forward: GCCCATTGTTTGACCAGTTTG
Reverse: AGGCCGGTGATGCATGA
CAGTTCAAGCCTCCAGCCTATCTG
Cyp2b10 Forward: GGGAAAGCGCATTTGTCTTG
Reverse: GATGGACGTGAAGAAAAGGAACA
AAAGCATTGCCCGCAGCGAA
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